NCT07182838Active, not recruitingEarly phase 1
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of HIV (+) Patients
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1. Treat Infection of Multiple Gene Mutation HIV Virus Strains. 2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 12 Sept 2025
- Start date
- 5 Oct 2026
- Primary completion date
- 18 Jun 2027
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
- Diseases
- HIV
- NCT number
- NCT07182838
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 5 Oct 2026 to the primary completion date, 18 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe or Critical Illness Severity
- The patients with other serious inter-current illness
- Serious Allergy
Other
- Pregnancy
- Breast-feeding
- Serious Bleed or Clot Tendency
- Serious side-effects of the biological product
- The prohibition of the biological product
Who the study is looking for
- HIV Positive
- Positive testing by standard RT-PCR assay or equivalent testing
- No AIDS Symptoms
- No clinical signs indicative of Severe or Critical Illness Severity
- Sign Informed Consent Form
Criteria the registry did not label
- Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients.
- 20 HIV (+) patients
Age in the registry: 24 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medicine Invention Design Incorporation - IORG0007849 - NPI 1023387701 Coordinator of this site? Confirm its status | Rockville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.